Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
OphtiMed Rx
OphtiMed Rx Overview
OphtiMed Rx is developing a novel molecular therapy for dry age-related macular degeneration (AMD), a common eye disease leading to blindness. The company’s treatment protects retinal cells from senescence (cellular aging) and can halt the progression of dry AMD.
OphtiMed Rx’s therapy is designed to prevent the loss of vision and independence caused by dry AMD, providing an enormous benefit to patients.